A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study

This study is testing a combination of two drugs — fruquintinib (a targeted therapy) and serplulimab (an immunotherapy) — as a third-line treatment for people with advanced colorectal cancer that has spread to multiple sites beyond just the liver. This is for patients whose cancer has stopped responding to two prior standard treatment regimens. **You may be eligible if...** - You are 18 or older with confirmed advanced or metastatic colorectal cancer - Your cancer has spread to sites other than just the liver (e.g., lungs, peritoneum) - Your cancer is classified as microsatellite stable (MSS or MSI-L) or mismatch repair proficient (pMMR) - You have received and progressed on two prior lines of standard chemotherapy - Your overall health (ECOG 0-2) and organ function are adequate **You may NOT be eligible if...** - Your cancer is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) - You have previously received PD-1, PD-L1, or CTLA-4 immunotherapy - You have active autoimmune disease or a history of serious immune-related complications - You are HIV positive or have active hepatitis B or C - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.